"I love Cantex Pharmaceuticals | Developing Novel Treatments for Inflammatory Lung Diseases and Cancer"

2022-08-20 13:17:30

OurCompanyAbout UsLeadershipOurScienceOurPipelineTherapeuticTargetsLatestNewsContactUsOurCompanyAbout UsLeadershipOurScienceOurPipelineTherapeuticTargetsLatestNewsContactUs Developing novel, well tolerated, treatments of cancer and inflammatory lung diseasesCantex has obtained exclusive worldwide rights from vTv Therapeutics to develop and commercialize azeliragon, a novel antagonist of RAGE (the receptor for advanced glycation endproducts)LEARN MORECantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well tolerated, treatments of cancer and inflammatory lung diseasesCantex is led by Stephen Marcus, M.D., and Neil Flanzraich, seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experienceREAD MORE Azeliragon targets cancer and its complications as well as inflammatory lung diseasesDicopp®, targets pediatric sarcomaDSTAT for traumatic injury and hemorrhagic shockREAD MORE February 24, 2022 – Cantex Pharmaceuticals, Inc. announced that it has secured a global license from Harvard University’s Office of Technology Development (OTD) to further develop Cantex’s drug azeliragon into a treatment for inflammatory lung diseases including COVID-19.READ MORESeptember 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.READ MORE DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML) LEARN MORE Cantex Pharmaceuticals, Inc.1792 Bell Tower LaneWeston, FL [email protected](954) 315-3660 Copyright © Cantex Pharmaceuticals, Inc. All rights reserved.